1. Алексеев Б.Я. Гормональная терапия в комбинированном лечении РПЖ. Вместе против рака 2004; 3: 35–8.
2. Бухаркин Б.В. Гормональное лечение местнораспространенного и диссеминированного рака предстательной железы. Под ред. проф. Б.П.Матвеева. Клиническая онкоурология. М., 2003; 560–3.
3. EAU Guidelines on Prostate Cancer. EurUrol 2008; 53: 68–80.
4. Joniau S, Hsu C-Y, Lerut E et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007; 51: 388–96.
5. Ward JF, Slezak JM et al. H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Br J Urol Int 2005; 95: 751–6.
6. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II. The effect of castration on advanced carcinoma of prostate gland. Arch Surg 1941; 43: 209–2.
7. Александров В.П. Рак предстательной железы. Пособие для врачей по диагностике, стадированию и лечению. СПбМАПО, 2004.
8. Каприн А.Д. и др. Лечение гормоночувствительного рака предстательной железы с использованием Калумида (Бикалутамид). Рус. мед. журн. 2006; 14 (14): 1062–4.
9. Bayar DP. VACURG/Studies on prostatic cancer and its treatment. In: Urollogical Pathology: The prostate (Tannenbaum M. ed.). New York; Lea and Febiger, 1977; 241–67.
10. Kumar S, Shelley M, Harrison C et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; CD006019.
11. Patel R Vipul, Leveillee J Raymond, Shah D Asha. Prostate Cancer: Neoadjuvant Androgen Deprivation. Emedicine from WebMed May 25, 2006.
12. Labrie F, Dupont A, Cusan L et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Lupron: the first controlled and randomized trial. Clin Invest Med. Dec 1993; 16 (6): 499–509.
13. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167 (1): 112–6.
14. Schulman CC, Sassine AM. Neoadjuvant hormonal deprivation before radical prostatectomy. Clin Invest Med 1993; 16 (6): 523–31.
15. GleaveM,Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500–7.
16. Debruyne FM, Witjes WP, Schulman CC et al. A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment. Eur Urol 1994; 26 (Suppl. 1): 4.
17. Soloway MS, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154 (2 Pt 1): 424–8.
18. Goldenberg SL, Klotz LH, Srigley J et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996; 156 (3): 873–7.
19. Van Poppel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro – Oncological Study Group. J Urol 1995; 154 (2 Pt 1): 429–34.
20. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (3A Suppl.): 65–9.
21. Aus G, Abrahamsson PA, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998; 159 (6): 2013-6.
22. Amling C. How the addition of hormones improves outcome: hormone therapy and surgery. Eur Urol 2004; Suppl. 3: 27–31.
23. Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 2016–9.
24. Gleave ME, Goldenberg SL, Jones EC et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213–9.
25. Gleave ME, Goldenberg SL, Сhin JL et al. Canadian Uro-Oncology Group. Randomised comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500–6.
26. Gleave ME, La Bianca SE, Goldenberg SL et al. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 289–94.
27. Charing CR., Rundle JS. Flushing: Long term side-effect of orchidectomy in the treatment of carcinoma of the prostate. J Urol 1988; 139: 478A.
28. Kaisary AV, Tyrrel CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–8.
29. Русаков И.Г., Алексеев Б.Я. Гормонотерапия генерализованного рака предстательной железы. Consilium Medicum 2000; 2 (3): 68–71.
30. Rosendahl I et al. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. The Prostate 1999; 38 (2): 100–9.
31. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide)150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389–96.
32. Boccardo F, Rubagotti A, Barichello M et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027–38.
33. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164 (5): 1579–82.

П.И.Раснер, Д.Ю.Пушкарь, А.В.Говоров

Кафедра урологии МГМСУ, Москва